Skip to content
Open access

New-Generation Transcatheter Valves for Extremely Small Aortic Annuli

Aug 2026 · JACC: Asia · Vol 6, pp. 2319 - 2330 · 1 citation · 19 references
Medicine

Abstract

Background Patients with extremely small aortic annuli are at increased risk of residual gradients and prosthesis-patient mismatch (PPM) after transcatheter aortic valve replacement (TAVR). Comparative data on contemporary valve platforms in this subset remain limited. Objectives The authors aimed to compare early clinical and hemodynamic outcomes among balloon-expandable valves (BEVs), supra-annular self-expanding valves (SA-SEVs), and intra-annular self-expanding valves (IA-SEVs) in patients with severe aortic stenosis and extremely small annuli. Methods Patients with annular area <314 mm2 from the OCEAN-TAVI registry were analyzed using multinomial propensity score overlap weighting. Primary outcomes were severe PPM, mean transvalvular pressure gradient ≥20 mm Hg, and paravalvular leakage (PVL) ≥mild. Results Among 385 patients, 125, 136, and 124 underwent BEV, SA-SEV, and IA-SEV implantation, respectively. Effective sample sizes after overlap weighting were 92.4, 93.6, and 85.4, with a median follow-up of 358 days. Adjusted probabilities of severe PPM were similarly low (1.6%, 2.0%, and 2.7%; P = 0.85). mean transvalvular pressure gradient ≥20 mm Hg occurred in 4.5%, 8.3%, and 2.3%, respectively (P = 0.19). PVL ≥mild was numerically more frequent with SEV than BEV (15.8%, 27.3%, and 27.0%; P = 0.09), with adjusted odds ratios versus BEV of 1.92 (95% CI: 0.96-3.84) for SA-SEV and 1.83 (95% CI: 0.91-3.70) for IA-SEV. Major complications and 1-year mortality were similar among groups. Conclusions Contemporary TAVR platforms showed broadly similar early outcomes, although PVL ≥mild was numerically more frequent with self-expanding valves.

Read PDF

Similar papers

Sep 2026

Long-term outcomes after balloon- or self-expandable transcatheter aortic valve replacement in small aortic annuli.

The need for further investigations using larger cohorts and contemporary devices to validate long-term comparative outcomes of BEV and SEV in patients with SAA is underscore the need for further investigations using larger cohorts and contemporary devices to validate long-term comparative outcomes.

T. Ryuzaki, Kentaro Hayashida, Kei Kamata et al. · 0 citations
Aug 2026

Newer-generation balloon-expandable vs. self-expanding transcatheter aortic valves: a propensity score matched analysis.

Among patients treated with newer-generation transcatheter valves, SEV demonstrated more favorable hemodynamic performance compared with BEV, however, short- and mid-term mortality rates remained similar between the two groups.

M. Baudo, S. Sicouri, Dimitrios E. Magouliotis et al. · 1 citation
Sep 2026

Impact of Aortic Annulus Size on Clinical and Hemodynamic Outcomes of Transcatheter Aortic Valve Implantation With the Navitor Valve

Patients with small aortic annuli undergoing transcatheter aortic valve implantation (TAVI) are at risk of higher residual transvalvular gradients. Evidence on the performance of new‐generation intra‐annular self‐expanding valves in this anatomical setting remains limited.

M. Casenghi, S. Corradetti, P. Paolisso et al. · 0 citations
Review Sep 2026

Aortic valve replacement in patients with small aortic annuli: a systematic review and network meta-analysis.

Objectives Up to 40% of patients with aortic stenosis undergoing valve replacement have a small annulus, a key determinant of valve hemodynamics, durability, and clinical outcomes. Surgical and transcatheter approaches have been reported to be determined by prosthesis design, considering the operative mortality and mor...

J. Chiabrando, M. Lombardi, E. Elia et al. · 0 citations
Open access Aug 2026

Redo-Transcatheter Aortic Valve Replacement With Self-Expanding Valves: A U.S. Registry Analysis.

In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR and support redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.

Toby Rogers, V. Bapat, S. Chetcuti et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.